State of the Art in Combination Immuno/Radiotherapy for Brain Metastases: Systematic Review and Meta-Analysis

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2022 May 27

PMID 35621634

Authors

Masoumeh Najafi

Amin Jahanbakhshi

Marzieh Gomar

Cinzia Iotti

Lucia Giaccherini

Omid Rezaie

Francesco Cavallieri

Letizia Deantonio

Lilia Bardoscia

Andrea Botti

Angela Sardaro

Salvatore Cozzi

Patrizia Ciammella

Affiliations

Soon will be listed here.

Abstract

Objectives: Common origins for brain metastases (BMs) are melanoma, lung, breast, and renal cell cancers. BMs account for a large share of morbidity and mortality caused by these cancers. The advent of new immunotherapeutic treatments has made a revolution in the treatment of cancer patients and particularly, as a new concept, if it is combined with radiotherapy, may lead to considerably longer survival. This systematic review and meta-analysis aimed to evaluate the survival rate and toxicities of such a combination in brain metastases.

Methods: To perform a systematic review of the literature until January 2021 using electronic databases such as PubMed, Cochrane Library, and Embase; the Newcastle-Ottawa Scale was used to evaluate the quality of cohort studies. For data extraction, two reviewers extracted the data blindly and independently. Hazard ratio with 95% confidence interval (CI), fixed-effect model, and inverse-variance method was calculated. The meta-analysis has been evaluated with the statistical software Stata/MP v.16 (The fastest version of Stata).

Results: In the first step, 494 studies were selected to review the abstracts, in the second step, the full texts of 86 studies were reviewed. Finally, 28 studies were selected consisting of 1465 patients. The addition of IT to RT in the treatment of brain metastasis from melanoma and non-small-cell lung carcinoma was associated with a 39% reduction in mortality rate and has prolonged overall survival, with an acceptable toxicity profile. The addition of IT to RT compared with RT alone has a hazard ratio of 0.39(95% CI 0.34-0.44).

Conclusions: A combination of immuno/radiotherapy (IR) for the treatment of patients with BMs from melanoma and non-small-cell lung carcinoma has prolonged overall survival and reduced mortality rate, with acceptable toxicity. In terms of timing, RT seems to have the best effect on the result when performed before or simultaneously with immunotherapy.

Citing Articles

Nutritional Assessment and Management of Patients with Brain Neoplasms Undergoing Neurosurgery: A Systematic Review.

Pebes Vega J, Mancin S, Vinciguerra G, Azzolini E, Colotta F, Pastore M Cancers (Basel). 2025; 17(5).

PMID: 40075613 PMC: 11898651. DOI: 10.3390/cancers17050764.

Case report of the first use of a hydrogel rectal spacer for prostate cancer reirradiation via LDR brachytherapy: applications and technical notes.

Lazrek A, Finocchi Ghersi S, Petre A, Houabes S, Serre A, Gassa F Front Oncol. 2025; 15:1494304.

PMID: 39949746 PMC: 11821462. DOI: 10.3389/fonc.2025.1494304.

Evidences on the Use of Hypofractionation in Postoperative/Salvage Radiotherapy for Prostate Cancer: Systematic Review of the Literature and Recent Developments.

Roukoz C, Lazrek A, Bardoscia L, Rubini G, Liu C, Serre A Cancers (Basel). 2025; 16(24.

PMID: 39766126 PMC: 11727527. DOI: 10.3390/cancers16244227.

Radiation drives tertiary lymphoid structures to reshape TME for synergized antitumour immunity.

Li S, Chen K, Sun Z, Chen M, Pi W, Zhou S Expert Rev Mol Med. 2024; 26:e30.

PMID: 39438247 PMC: 11505612. DOI: 10.1017/erm.2024.27.

Radiosurgery in Grade II and III Meningiomas: A Systematic Review and Meta-Analysis.

Jahanbakhshi A, Najafi M, Gomar M, Ciammella P, Ruggieri M, Iotti C J Pers Med. 2024; 14(8).

PMID: 39201994 PMC: 11355310. DOI: 10.3390/jpm14080802.

References

Demaria S, Bhardwaj N, McBride W, Formenti S . Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys. 2005; 63(3):655-66. PMC: 1489884. DOI: 10.1016/j.ijrobp.2005.06.032. View

Rahman R, Cortes A, Niemierko A, Oh K, Flaherty K, Lawrence D . The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. J Neurooncol. 2018; 138(2):299-306. DOI: 10.1007/s11060-018-2795-7. View

Long G, Atkinson V, Lo S, Sandhu S, Guminski A, Brown M . Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018; 19(5):672-681. DOI: 10.1016/S1470-2045(18)30139-6. View

Goldberg S, Gettinger S, Mahajan A, Chiang A, Herbst R, Sznol M . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016; 17(7):976-983. PMC: 5526047. DOI: 10.1016/S1470-2045(16)30053-5. View

Kotecha R, Miller J, Venur V, Mohammadi A, Chao S, Suh J . Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome. J Neurosurg. 2017; 129(1):50-59. DOI: 10.3171/2017.1.JNS162797. View

Belgioia L, Desideri I, Errico A, Franzese C, Daidone A, Marino L . Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: A literature review. Crit Rev Oncol Hematol. 2019; 133:163-170. DOI: 10.1016/j.critrevonc.2018.11.009. View

Tannir N, Signoretti S, Choueiri T, Mcdermott D, Motzer R, Flaifel A . Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. 2020; 27(1):78-86. PMC: 8589223. DOI: 10.1158/1078-0432.CCR-20-2063. View

Diao K, Bian S, Routman D, Yu C, Kim P, Wagle N . Combination ipilimumab and radiosurgery for brain metastases: tumor, edema, and adverse radiation effects. J Neurosurg. 2018; 129(6):1397-1406. PMC: 7469982. DOI: 10.3171/2017.7.JNS171286. View

Franceschini D, Franzese C, Navarria P, Ascolese A, De Rose F, Del Vecchio M . Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?. Cancer Treat Rev. 2016; 50:1-8. DOI: 10.1016/j.ctrv.2016.08.003. View

10.

Liniker E, Menzies A, Kong B, Cooper A, Ramanujam S, Lo S . Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016; 5(9):e1214788. PMC: 5048757. DOI: 10.1080/2162402X.2016.1214788. View

11.

Motzer R, Escudier B, Mcdermott D, Frontera O, Melichar B, Powles T . Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020; 8(2). PMC: 7359377. DOI: 10.1136/jitc-2020-000891. View

12.

Silk A, Bassetti M, West B, Tsien C, Lao C . Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med. 2014; 2(6):899-906. PMC: 3892394. DOI: 10.1002/cam4.140. View

13.

Kiess A, Wolchok J, Barker C, Postow M, Tabar V, Huse J . Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015; 92(2):368-75. PMC: 4955924. DOI: 10.1016/j.ijrobp.2015.01.004. View

14.

Manon R, ONeill A, Knisely J, Werner-Wasik M, Lazarus H, Wagner H . Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol. 2005; 23(34):8870-6. DOI: 10.1200/JCO.2005.01.8747. View

15.

Schapira E, Hubbeling H, Yeap B, Mehan Jr W, Shaw A, Oh K . Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. Int J Radiat Oncol Biol Phys. 2018; 101(3):624-629. DOI: 10.1016/j.ijrobp.2018.02.175. View

16.

Mathew M, Tam M, Ott P, Pavlick A, Rush S, Donahue B . Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res. 2013; 23(3):191-5. DOI: 10.1097/CMR.0b013e32835f3d90. View

17.

Trapani S, Manicone M, Sikokis A, DAbbiero N, Salaroli F, Ceccon G . Effectiveness and safety of "real" concurrent stereotactic radiotherapy and immunotherapy in metastatic solid tumors: a systematic review. Crit Rev Oncol Hematol. 2019; 142:9-15. DOI: 10.1016/j.critrevonc.2019.07.006. View

18.

Franceschini D, De Rose F, Cozzi S, Franzese C, Rossi S, Finocchiaro G . The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art. Crit Rev Oncol Hematol. 2020; 148:102894. DOI: 10.1016/j.critrevonc.2020.102894. View

19.

Matsui Y . Current Multimodality Treatments Against Brain Metastases from Renal Cell Carcinoma. Cancers (Basel). 2020; 12(10). PMC: 7600559. DOI: 10.3390/cancers12102875. View

20.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View